
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Catalyst Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
Details : Firdapse (amifampridine) is an oral, nonspecific, voltage-dependent, potassium channel blocker that is indicated to treat Lambert-Eaton myasthenic syndrome.
Product Name : Firdapse
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 21, 2025
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Catalyst Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Catalyst Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Catalyst Pharma Sub-Licensee Gets Approval For FIRDAPSE® in Japan
Details : Firdapse (amifampridine) is an oral, nonspecific, voltage-dependent, potassium channel blocker that received approval to treat Lambert-Eaton myasthenic syndrome in Japan.
Product Name : Firdapse
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 24, 2024
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Catalyst Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Recipient : Catalyst Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Firdapse (amifampridine) is an oral, nonspecific, voltage-dependent, potassium (K+) channel blocker that causes depolarization of the presynaptic membrane and slows or inhibits repolarization.
Product Name : Firdapse
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 18, 2023
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Recipient : Catalyst Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Recipient : Catalyst Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Firdapse (amifampridine phosphate) is a broad spectrum potassium channel blocker. Amifampridine is the only evidence-based, FDA-approved treatment for adult patients with Lambert-Eaton Myasthenic Syndrome (LEMS).
Product Name : Firdapse
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 06, 2021
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Recipient : Catalyst Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Recipient : Catalyst Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : DyDo Pharma will have joint rights to develop Firdapse® (amifampridine phosphate), and exclusive rights to commercialize the product, in Japan. Firdapse® is an oral, nonspecific, voltage-dependent, potassium (K+) channel blocker that slows or inhibits ...
Product Name : Firdapse
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 28, 2021
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Recipient : Catalyst Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Contact Us!